Article Information
Published By
Online ISSN
History
- Published online October 13, 2022.
Article Versions
- You are currently viewing a previous version of this article (October 13, 2022 - 06:04).
- View the most recent version of this article
Copyright & Usage
Copyright ©The authors 2022 This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
Author Information
- Florian Tran1,2⇑,
- Danielle MM Harris1,3,
- Alena Scharmacher1,
- Hanna Graßhoff4,
- Kristina Sterner4,
- Susanne Schinke4,
- Nadja Käding5,
- Jens Y Humrich4,
- Otávio Cabral-Marques6,7,8,
- Joana p Bernardes1,
- Neha Mishra1,
- Thomas Bahmer2,9,
- Jeanette Franzenburg1,10,
- Bimba F Hoyer11,
- Andreas Glück2,
- Martina Guggeis1,2,
- Alexander Ossysek1,
- Andre Küller12,
- Derk Frank12,13,
- Christoph Lange14,15,16,17,
- Jan Rupp5,
- Jan Heyckendorf2,14,15,18,
- Karoline I Gaede15,18,19,
- Howard Amital20,
- Philip Rosenstiel1,
- Yehuda Shoenfeld20,21,22,
- Gilad Halpert20,
- Avi Z Rosenberg23,
- Kai Schulze-Forster24,
- Harald Heidecke24,
- Gabriela Riemekasten3,25,26 and
- Stefan Schreiber1,2,26
- 1Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany
- 2Department of Internal Medicine I, University Medical Center Schleswig-Holstein, Kiel, Germany
- 3Institute for Human Nutrition and Food Science, University Medical Center Schleswig-Holstein, Kiel, Germany
- 4Department of Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein, Lübeck, Germany
- 5Department of Infectious Diseases and Microbiology, University Medical Center Schleswig-Holstein, Lübeck, Germany
- 6Departamento of Imunologia, Instituto de Ciencias Biomedicas, Universidade de São Paulo, São Paulo, SP, Brazil
- 7Departamento of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, SP, Brazil
- 8Network of Immunity in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Sao Paulo, Brazil
- 9LungenClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany
- 10Institute of Clinical Chemistry, University Medical Center Schleswig-Holstein, Kiel, Germany
- 11Section for Rheumatology, Department of Internal Medicine I, University Medical Center Schleswig-Holstein, Kiel, Germany
- 12Department of Internal Medicine III, University Medical Center Schleswig-Holstein, Kiel, Germany
- 13German Centre for Cardiovascular Research (DZHK), partner site Hamburg, Kiel, Lübeck, Germany
- 14Research Center Borstel, Borstel, Germany
- 15German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems, Borstel, Germany
- 16Respiratory Medicine & International Health/ University of Lübeck, Lübeck, Germany
- 17Baylor College of Medicine and Texas Childreńs Hospital, Houston, TX, USA
- 18Airway Research Center North (ARCN), Members of the German Center for Lung Research (DZL), Borstel, Gemany
- 19Research Center Borstel, Borstel, Germany, BioMaterialBank Nord (BMB Nord), Germany
- 20Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Ramat-Gan, Israel
- 21Ariel University, Ariel, Israel
- 22Laboratory of the Mosaic of Autoimmunity, Saint Petersburg State University, Saint-Petersburg, Russia
- 23Department of Pathology, Johns Hopkins University, Baltimore, MD , USA
- 24CellTrend GmbH, Im Biotechnologiepark 3, Luckenwalde, Germany
- 25Priority Area Asthma & Allergy, Research Center Borstel, Airway Research Center North (ARCN), Members of the German Center for Lung Research (DZL), Borstel, Germany
- 26Co-last authors
- Corresponding author: Florian Tran (f.tran{at}ikmb.uni-kiel.de)
Funding
BMBF iTREAT project
3TR (IMI2JU)
DFG Research Unit 5042 "miTarget"
Cluster of Excellence 2167 "Precision Medicine in Chronic Inflammation"
RTF-VIState Schleswig-Holstein
COVID-reponse grant
Article usage
Altmetrics
Vol 9 Issue 1
Table of Contents
Increased protease-activated receptor 1 autoantibodies are associated with severe COVID-19
